Mathematical Modeling of Tumor Immune Interactions: A Closer Look at the Role of a PD-L1 Inhibitor in Cancer Immunotherapy by Radunskaya, Ami et al.
Spora: A Journal of Biomathematics
Volume 4 | Issue 1 Article 3
2018
Mathematical Modeling of Tumor Immune
Interactions: A Closer Look at the Role of a PD-L1
Inhibitor in Cancer Immunotherapy
Ami Radunskaya
Pomona College, aer04747@pomona.edu
Ruby Kim
Pomona College, rubyshkim@gmail.com
Timothy Woods II
Pomona College, tw002014@mymail.pomona.edu
Follow this and additional works at: https://ir.library.illinoisstate.edu/spora
Part of the Ordinary Differential Equations and Applied Dynamics Commons
This Mathematics Research is brought to you for free and open access by ISU ReD: Research and eData. It has been accepted for inclusion in Spora: A
Journal of Biomathematics by an authorized editor of ISU ReD: Research and eData. For more information, please contact ISUReD@ilstu.edu.
Recommended Citation
Radunskaya, Ami; Kim, Ruby; and Woods II, Timothy (2018) "Mathematical Modeling of Tumor Immune Interactions: A Closer
Look at the Role of a PD-L1 Inhibitor in Cancer Immunotherapy," Spora: A Journal of Biomathematics: Vol. 4: Iss.1, 25–41.
DOI: http://doi.org/10.30707/SPORA4.1Radunskaya
Available at: https://ir.library.illinoisstate.edu/spora/vol4/iss1/3
Mathematical Modeling of Tumor Immune Interactions: A Closer Look at
the Role of a PD-L1 Inhibitor in Cancer Immunotherapy
Cover Page Footnote
We thank the Pomona College SURP (Summer Undergraduate Research Program) for support.
This mathematics research is available in Spora: A Journal of Biomathematics: https://ir.library.illinoisstate.edu/spora/vol4/iss1/3
ISSN 2473-3067 (Print)
ISSN 2473-5493 (Online)
Mathematical Modeling of Tumor Immune Interactions:
A Closer Look at the Role of a PD-L1 Inhibitor
in Cancer Immunotherapy
Ruby Kim1, Timothy Woods1, Ami Radunskaya1,*
*Correspondence:
Prof. Ami Radunskaya,
Mathematics Department,
Pomona College,
610 N. College Avenue,
Claremont, CA 91711, USA
aradunskaya@pomona.edu




Abstract
Monoclonal antibodies have shown promising results as a form of cancer immunotherapy used
either alone or in combination with another treatment. We model a monoclonal antibody
in combination with a dendritic cell (DC) vaccine in order to study treatment optimization.
Certain proteins on tumor cells allow the tumor cells to bind to specific receptors on immune
cells, rendering the immune cells ineffective. Experiments using mouse models show that
a combination of antibodies to these proteins with tumor suppressing drugs improves the
effectiveness of cancer vaccines. We create independent models of each of the two treatments
in combination with DC therapy, fit them to experimental data, and create a final, data-
informed model of the combined treatment. This new model can be used to develop novel
therapies involving monoclonal antibodies.
Keywords: tumor-immune model, cancer vaccines, immunotherapy, PD-L1 inhibitor
1 Introduction
Immunology is a scientific discipline that explores the
development and function of the immune system. The
immune system comprises many cells, including T cells
and B cells, as well as lymphoid organs. When infections
arise, the cells and lymphoid organs in the immune sys-
tem work together to fight off pathogens and keep the
immune system healthy and functioning [11]. T cells are
a type of white blood cell crucial to the adaptive immune
system because of their ability to protect the body against
harmful pathogens. Programmed death-1 (PD-1) recep-
tors on active T cells are being widely studied for their
role in regulating T cell activity. PD-1 receptors bind
to programmed death-ligand 1 (PD-L1), often on other
immune cells, creating a natural pathway that suppresses
T cell activity and helps prevent autoimmunity. Research
shows that some tumor cells express PD-L1. This allows
them to take advantage of PD-1/PD-L1 immune regula-
tion and evade the T cell response [14]. Figure 1 below
illustrates a side-by-side depiction of the binding interac-
tion between the PD-1 receptor and PD-L1 ligand, as well
as an anti-PD-L1 treatment blocking the pathway. The
PD-1/PD-L1 pathway suppresses T cell receptor (TCR)
signaling necessary for tumor identification by T cells.
This ability of tumor cells to evade the immune response
has been partially responsible for the limited success of
1Mathematics Department, Pomona College, Claremont, CA
Figure 1: Tumor cells take advantage of the PD-1/PD-
L1 pathway to evade the immune response by inhibiting
TCR signaling (left). Anti-PD-L1 binds to PD-L1 and
blocks the pathway, allowing the T cell to discern the
tumor cell (right).
cancer vaccines to date. Ongoing research shows the
potential efficacy of PD-1/PD-L1 pathway inhibitors in
cancer therapy. Anti-PD-L1 monoclonal antibodies have
benefited patients in clinical trials, though they have yet
to be implemented in practice [12].
Experiments conducted by [24] show that the combi-
nation of anti-PD-L1 and ibrutinib creates an effective
response against J558 cancer cells in mouse models. Ibru-
tinib is an orally administered anti-cancer drug that in-
hibits Bruton’s tyrosine kinase (BTK) activity; the ex-
pression of BTK in tumor cells is associated with in-
creased proliferation and survival [24].
In this paper, we develop a mathematical model that
explores the effects of PD-1/PD-L1 therapy in combina-
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tion with immunotherapy. In particular, we are inter-
ested in the effects of anti-PD-L1 therapy in conjunction
with dendritic cell (DC) vaccines. Finally, we look at
the effect of adding an anti-cancer drug to these other
therapies. Combination therapies are a common line of
attack in treating cancer, and mathematical models can
help unravel the complex interactions between the various
treatments.
Dendritic cells are antigen-presenting cells that activate
T cells to create an immune response. Upon encountering
antigens, or foreign substances, dendritic cells mature and
travel to the lymphoid organs where they present these
antigens to T cells. The T cells then begin to proliferate
and become active T cells or memory T cells. Active
T cells presented with a tumor antigen travel to the tumor
site to identify and destroy tumor cells, while memory
T cells reside in the blood and lymphoid organs to prepare
for future attacks [13].
Many mathematical models have been created in the
past to study the interactions between tumor cells and the
immune response in the context of dendritic cell vaccines.
One existing model focuses on three main populations:
regulatory T cells, helper T cells, and dendritic cells, and
their response to tumor growth [22]. The equations focus
on immunosuppression mechanisms to simulate dendritic
cell vaccines. Another model uses a system of partial
differential equations to simulate anti-PD-L1 along with
DC vaccines [18]. While these models present interest-
ing findings, we utilize a differential equations model [16]
as our basis because it uniquely accounts for important
mechanisms that take place in the spleen. This model, in
turn, is based on a previous model of the immune acti-
vation and tumor-immune interactions that incorporates
time delays [6]. We have confirmed the model presented
in [16] using experimental data provided by [24]. This pre-
liminary model studies dendritic cell vaccines using three
compartments of differential equations. These equations
describe the interactions between tumor cells, T cells, and
dendritic cells throughout the spleen, blood, and tumor
compartments.
In this paper, we present a modification of the model
given in [16] to incorporate the effect of anti-PD-L1 on
the tumor-immune kinetics. We also add the effect of
ibrutinib, a drug that slows tumor growth. Exploring
combination therapies is difficult in a clinical setting, so
mathematical models can suggest how combinations of
different treatments might affect outcomes [5]. The ex-
tended model developed in this paper would aid in the
design of novel therapies, and, through in silico experi-
ments, can be used to optimize treatment combinations
and dosing methods.
Figure 2: DCs (D), active T cells (Ea), and memory
T cells (Em) travel between the spleen, blood, and tumor
compartments. Natural cell deaths of these populations,
including proliferating cells (P) and tumor cells (T), are
indicated by “cell death.” The spleen compartment addi-
tionally contains conglomerate cells, DCs binded to naive
T cells for activation. The model accounts for potential
DC-therapy injections into the bloodstream and/or tu-
mor site.
2 Background: Previous Model
The initial model from [16] consists of eleven differen-
tial equations in three compartments: spleen, blood, and
tumor. The equations model the dynamics between den-
dritic cells, tumor cells, and activated/memory T cells.
Figure 2 below illustrates an overview of the three com-
partments and their cell populations.
2.1 Spleen Compartment
In the spleen compartment, we observe interactions be-
tween three cell populations: dendritic cells, activated
T cells, and memory T cells, each denoted by Dspleen,
Easpleen, and E
m
spleen, respectively. Both the activated
T cells and memory T cells enter the spleen from the
blood at a rate of µBSE , while dendritic cells travel from
the blood to the spleen at a rate of µBS . In addition to
the entrance rates of the cells, we have the natural death
rates of each cell population, marked by the parameters
aD, aEaspleen , and aEmspleen , for dendritic cells, activated
T cells, and memory T cells, respectively.
After presentation of tumor-specific antigen to tumor
cells by dendritic cells, the two cells attach to form a con-
glomerate represented by the population W in the model.
Conglomerate cells enter the W population at a rate of γ
and leave at a rate of λ, after the dendritic cell detaches
from the conglomerate and deactivates. Newly activated
T cells then enter the proliferating cell (P) population at
a rate of ωλ to proliferate, where ω represents the aver-
age amount of nascent T cells that bind with dendritic
cells. If you recall from earlier, after dendritic cells bind
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to nascent T cells, T cells become activated and begin to
proliferate. After this expansion phase, active T cells exit
the spleen, while remaining cells become memory T cells
available for later use against returning pathogens.
Memory T cells enter the P compartment for prolifer-
ation at a rate of λm. Activated T cells are released from
the spleen into the blood at a rate that depends on how
much antigen is present. This is captured in the terms in
parentheses in equations (2) and (3). T cells remain in
the proliferation, or expansion phase for an average time
of 1
βE
, and die at a rate of βD. These rates are combined
in the model in the parameter β = βE − βD (5).
d
dt
Dspleen = µBSDblood − (aD + γ)Dspleen + λW (1)
d
dt
Easpleen = µBSEE
a
blood − ramEaspleen − aEaSEaspleen
−
(
µ∗SB +
µnormal−µ∗SB
1 +
Dspleen
θshut
)
Easpleen
+ βEP (2)
d
dt
Emspleen = µBSEE
m
blood + ramE
a
spleen − aEmEmspleen
−
(
µ∗SB +
µnormal−µ∗SB
1 +
Dspleen
θshut
)
Emspleen
− λmEmspleenDspleen (3)
d
dt
W = γDspleen − λW (4)
d
dt
P = ωλW + λmEmspleenDspleen − βP (5)
2.2 Blood Compartment
The blood compartment serves as a vessel for cells to
travel back and forth between the spleen and the tumor
compartments. The cell populations present in the blood
are dendritic cells, activated T cells, and memory T cells,
corresponding to Dblood, E
a
blood, and E
m
blood, respectively.
Cells are neither created nor destroyed in the blood com-
partment, since the blood compartment is merely a site
for cell transportation. The rate at which the cells travel
through the compartments are given by µB , µTB , µ
∗
SB ,
µBB , and µnormal. The term vblood(t) illustrates the pro-
tocol for dendritic cell injection into the bloodstream.
d
dt
Dblood = −µBDblood + µTBDtumor + vblood(t) (6)
d
dt
Eablood =
(
µ∗SB +
µnormal − µ∗SB
1 +
Dspleen
θshut
)
Easpleen
− µBBEablood (7)
d
dt
Emblood =
(
µ∗SB +
µnormal − µ∗SB
1 +
Dspleen
θshut
)
Emspleen
− µBBEmblood (8)
2.3 Tumor Compartment
The tumor compartment illustrates the interaction be-
tween activated T cells and tumor cells. The popula-
tions in the tumor compartment are given by Eatumor, T ,
Dtumor, for activated T cells, tumor cells, and dendritic
cells, respectively. As described in Section 2.1, T cells are
activated in the spleen and travel to the tumor compart-
ment to mount their attack on the tumor cells. The term
d is a kill rate for the tumor cells by the activated T cells,
characterizing the effectiveness of the activated T cells in
eliminating the tumor cells. The ratio-dependent kill rate
in equation (12) is derived in [7].
d
dt
Eatumor = µBB
T
α+ T
Eablood − aEaTEatumor
− cEatumorT (9)
d
dt
T = rT
(
1− T
k
)
−DT (10)
d
dt
Dtumor =
mT
q + T
− (µTB + aD)Dtumor
+ vtumor(t) (11)
where
D = d
(
Eatumor
T
)l
s+
(
Eatumor
T
)l (12)
This portion of the model is extended in sections 4.2
and 5.2 by the addition of new treatments. For all simu-
lations, we use a non-dimensionalized form of this model
provided in Appendix B of [16]. All parameters are de-
scribed in Appendix A of this paper.
3 Experimental Data
Data from mouse models show that a combination of anti-
PD-L1 and ibrutinib creates an effective response against
J558 cancer cells in mice (Figure S6 in [24]). 6–8 week
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old female BALB/c mice were inoculated with tumor cells
subcutaneously, and tumor growth was monitored every 2
to 3 days. There were four treatment groups with thirteen
mice per group: non-treated, ibrutinib, anti-PD-L1, and
a combination of ibrutinib and anti-PD-L1. The initial
size of the tumor injected was 5×106 cells for each mouse.
3.1 Initial Parameter Fitting
In order to capture individual variations in the tumors of
the mice, we fit two parameters to each growth curve in
the untreated group of mice in [24]: d (maximum kill rate)
and r (tumor growth rate). Note that we call d the max-
imum kill rate because the per-cell kill rate represented
by the function D given in Equation (12) approaches d
as the ratio of active T cells to tumor cells, Eatumor/T ,
goes to infinity. These are the patient-specific parameters
with the greatest influence on tumor size [16]. We note
that the range of parameter values obtained is quite large,
particularly for the parameter d, the maximum kill rate
of tumor cells by immune cells. This parameter is also
quite a bit smaller than the parameter value estimated in
[16], presented in Appendix A. This makes sense, since
the type of mice used, the BALB/c strain, are bred to be
immuno-deficient. For the same reason, we are not sur-
prised that the parameter r is generally larger than the
estimate from [16]. The other model parameters are car-
ried over from the original model presented in [16]. We
used the MATLAB fminsearch function to minimize the
squared distance of the model simulations to the data
points for each curve in the data. Results of the data
fitting are shown in Figure 3.
Tumor population curves in this control group resemble
an exponential curve, or the beginning of a logistic curve.
We assume that the growth law is logistic, rather than
exponential, since this is a more realistic model. A tumor
cannot grow without bound; its size is limited by avail-
able resources such as space and nutrients. For a more
thorough discussion of growth models, see [25]. Fitted
parameter values d and r for each curve are listed in Ta-
ble 1. All other parameter values were maintained from
the original model, and are provided in Appendix A.
3.2 Success with anti-PD-L1
Having confirmed that the initial model follows experi-
mental data, we are interested in modeling ibrutinib and
anti-PD-L1 treatments. In their study, [24] administered
24 mg/kg body weight of ibrutinib on days 12–20 after
tumor inoculation for the ibrutinib group, and injected
0.2 mg of an anti-PD-L1 antibody every other day for the
anti-PD-L1 group. Then, the two treatments were given
simultaneously to the combination group. The ibruti-
nib treatment alone did not make statistically significant
d r
Curve 1 0.2045 0.3909
Curve 2 2.65E-04 0.2828
Curve 3 0.0298 0.2828
Curve 4 6.61E-05 0.2621
Curve 5 6.61E-05 0.2587
Curve 6 0.1285 0.287
Curve 7 0.1352 0.287
Curve 8 0.029 0.249
Curve 9 0.0716 0.2546
Curve 10 0.1017 0.2546
Curve 11 6.61E-05 0.2156
Curve 12 6.61E-05 0.2062
Curve 13 0.0603 0.209
Table 1: Each curve fits data for each mouse from the
non-treated group in [24]. Fitted d and r values in the
table represent individual differences in immune ability
and tumor growth.
changes; however, anti-PD-L1 and the combined treat-
ment both significantly improved survival, with greater
success from the combined treatment [24].
4 Model with Ibrutinib
When modeling the effects of a drug on the system, it is
important to consider how quickly the drug arrives at the
site of action, and how quickly it is eliminated. These
dynamics are called the “pharmacokinetics” of the drug.
We use an exponential decay model for the amount of
ibrutinib in the tumor compartment to capture the clear-
ance of the drug near the tumor site. Ibrutinib was given
by oral gavage every day from days 12–20 at a dosage
of 24 mg/kg body weight. We approximate the arrival
of the drug at the tumor site as happening immediately
after the dosage is given. The details of the assumptions
for the pharmacokinetic modeling are given below.
4.1 Assumptions
1. Ibrutinib activates at the site of the tumor. Model
changes are made only in the tumor compartment
for simplicity.
2. Ibrutinib decays exponentially. The half-life of ibru-
tinib is 4–6 hours [8]. Assuming an average half-
life of 5 hours, the decay constant is calculated to
be 3.3271.
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Figure 3: Model predictions using equations (10) and (12) are compared to data from the untreated group of [24]
experiments. In the color-printed version, the colors of the curves and their corresponding data points alternate for
easier visibility.
Figure 4: Model predictions are compared to data from the ibrutinib treatment group [24]. Parameters d, r, and
cib are fit using MATLAB’s fminsearch to minimize the sum of squared residuals. In the color-printed version, the
colors of the curves alternate for easier visibility.
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3. Ibrutinib inhibits Bruton’s tyrosine kinase (BTK)
activity, which is important for tumor growth [20].
Hence, the tumor growth term is effected by the pres-
ence of ibrutinib. BTK is a protein in the body
responsible for the production and maturation of
B cells, which are vital in the fight against infec-
tion [9]. Similarly, BTK expression in tumor cells
precipitates an increase in production of tumor cells.
4. 6–8 week old female BALB/c mice have an average
weight of 16 grams [2]. An ibrutinib dosage of ap-
proximately 24 × 0.016 = 0.384 mg was used in the
experiments [24].
5. We approximate the amount of ibrutinib added to
the tumor site by simply using the amount adminis-
tered at each time step.
4.2 Model Development
Let X(t) be the amount of ibrutinib at the site of the
tumor at time t. Following our assumption of the drug’s
exponential decay,
d
dt
X = −δX (13)
where δ = 3.3271 is the decay constant of ibrutinib. We
adjust our tumor growth equation (10) to describe ibru-
tinib’s stunting of the tumor growth rate. Data from [23]
suggest a reverse sigmoid curve for the performance of
ibrutinib depending on the drug’s dosage. The percentage
of tumor cells decreases as more ibrutinib is introduced.
A preliminary fit using a decreasing function of ibruti-
nib concentration to model its impact on tumor growth
rate reveals that a reciprocal function, described in de-
tail below, adequately captures the dynamics observed in
experimental data, which is confirmed later in Figure 4.
In particular, we use a function of the form 11+cibX to
model the effect of ibrutinib dosage, X, on tumor growth
rate, where cib scales X to a non-dimensionalized value.
We obtain the following tumor growth equation that ac-
counts for the ibrutinib treatment:
d
dt
T =
r
1 + cibX
T
(
1− T
k
)
−DT (14)
The tumor compartment of the initial model is modified
to include the new ibrutinib equation (13) and the drug’s
effects on tumor growth (14).
We simulate the ibrutinib treatment by solving the final
system of differential equations in steps and increasing
the initial condition of X, the amount of ibrutinib at the
tumor site, by 0.384 mg at the beginning of days 12–20
after tumor inoculation.
d r
Curve 1 0.058 0.3006
Curve 2 0.1299 0.32
Curve 3 0.1953 0.3395
Curve 4 0.2091 0.3395
Curve 5 0.209 0.335
Curve 6 6.61E-05 0.2485
Curve 7 0.1693 0.2933
Curve 8 0.0585 0.2518
Curve 9 0.1697 0.282
Curve 10 0.1062 0.2447
Curve 11 6.61E-05 0.2085
Curve 12 0.0501 0.2127
Curve 13 0.1002 0.2091
Table 2: Each curve fits data for each mouse from the
ibrutinib treatment group in [24]. Fitted d and r values
in the table represent individual differences in immune
ability and tumor growth.
4.3 Parameter Fitting
We use the Nelder-Mead least squares algorithm by im-
plementing MATLAB’s fminsearch again to fit the newly
adjusted model to data from Sagiv-Barfi’s ibrutinib treat-
ment group [24]. We fit parameters d, r, and cib to each
curve, then compute the average ibrutinib scaling value
(cib) to be 6.61 × 10−5. We fix cib = 6.61 × 10−5 and fit
parameters d and r again. Values for each mouse are re-
ported in Table 2. Figure 4 depicts the model predictions
of tumor size over time against experimental data.
5 Model with anti-PD-L1
To model the amount of anti-PD-L1 at the tumor site,
we again use an exponential decay model to capture the
pharmacokinetics. The anti-PD-L1 antibody was IP in-
jected (into the body cavity) every other day.
5.1 Assumptions
1. Anti-PD-L1 decays exponentially at the tumor site,
with a half-life of 15 days [3] and decay constant of
0.0462 day−1.
2. Anti-PD-L1 injected at the tumor site binds to
PD-L1 on tumor cells, acting as a blocker that pre-
vents PD-L1 from binding to PD-1 receptors on ef-
fector immune cells. This fortifies the maximum kill
rate, d.
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3. Anti-PD-L1 injection began on day 5 on average,
with the antibody having an almost instantaneous
effect at the tumor site.
Let Z(t) be the amount of anti-PD-L1 at the site of the
tumor at time t. The blocker’s exponential decay can be
written as
d
dt
Z = −γZ (15)
where γ = 0.0462 is the decay constant of anti-PD-L1.
The performance of the PD-1/PD-L1 pathway blocker fol-
lows a sigmoid curve. Performance is defined by the abil-
ity of anti-PD-L1 to block immune checkpoint inhibitory
signals. [21] quantifies TCR-mediated luminescence, in-
dicating the amount of TCR activation depending on the
concentration of anti-PD-L1. Figure 5, recreated from
[21], illustrates anti-PD-L1 performance as anti-PD-L1
concentration increases. The figure utilizes a log-scale for
anti-PD-L1 concentrations to aid in the visualization of
sigmoidal behavior. Though data limitations make it dif-
ficult to observe graphically, this sigmoidal behavior is
consistent when using non-scaled anti-PD-L1 concentra-
tion values. From Figure 5, we can see how sensitive the
kill rate, as measured by activated T-cell receptors, is to
the concentration of the PD-L1 antibody. This motivates
the functional form that we choose for the dose-response
function, F , given in Equation (16).
Based on the assumption that the relationship between
anti-PD-L1 and T cell ability follows sigmoidal behavior,
we use F below to represent the blocker’s effect on the
kill term, dependent on Z, with cpd and kpd as our scaling
parameters. We will obtain fitted parameter values using
data from [24] again. A general sigmoid, or “switch”,
function can be written:
F = cpd − 1
pi
(
tan−1 ((Z − 1) · kpd) + pi
2
)
+ 1 (16)
Since anti-PD-L1 affects the kill rate of the tumor by
active T cells, we multiply the previous ratio-dependent
kill rate, (12), by (16) to give a new tumor growth equa-
tion:
d
dt
T = rT
(
1− T
k
)
−FDT (17)
Adding equations (15) and (17) to the original model
(9), (11) and (12) gives a model of tumor-immune inter-
actions in the presence of anti-PD-L1.
We simulate the anti-PD-L1 treatment by added a set
value to Z, the amount of anti-PD-L1 at the tumor site, at
the beginning of every other day, starting with day 5 after
tumor inoculation. This value corresponds to the dose of
0.2 mg given every two days. This instantaneous increase
in the amount of anti-PD-L1 at the tumor compartment
is a simplification that we chose because the time it takes
the antibody to reach the tumor site is negligible for a
treatment length of 25 days.
d r
Curve 1 0.0846 0.3492
Curve 2 0.0925 0.3492
Curve 3 0.0973 0.3495
Curve 4 0.0018 0.2569
Curve 5 0.0813 0.3091
Curve 6 0.0078 0.248
Curve 7 0.0961 0.3092
Curve 8 0.1011 0.3082
Curve 9 0.0947 0.2977
Curve 10 0.0909 0.2977
Curve 11 0.0942 0.2977
Curve 12 0.1279 0.2956
Curve 13 0.1208 0.2844
Table 3: Each curve fits data for each mouse from the
anti-PD-L1 treatment group in [24]. Fitted d and r values
in the table represent individual differences in immune
ability and tumor growth.
5.2 Parameter Fitting
We fit the newly adjusted model to data from the next
treatment group, anti-PD-L1 injected every other day
starting from day 5. We use the same parameter fitting
strategies to fit d, r, cpd, and kpd for each mouse, then fix
parameters cpd and kpd to their average values: cpd = 50
and kpd = 97. In our model fitting protocols, we first
calculated d and r values for each individual curve from
the Sagiv et al. experiments. Each new calculation for d
and r generated a scaling value for cpd and kpd. Hence,
we calculated the average cpd and kpd values to mini-
mize variation and obtain a fixed scaling value(s) for all
13 curves. Then, we adjust parameters d and r again to
obtain the best fit to each curve. These fits are shown in
Figure 6, and parameter values for d and r provided in
Table 3.
6 Combined Treatment
Experiments conducted by Sagiv et al. reveal that a com-
bination of ibrutinib and anti-PD-L1 treatments improves
survival in mouse models. Equations modeling both the
effects of ibrutinib and anti-PD-L1 are added to simu-
late the combined treatment for varying d and r values.
This new model combines both treatments with the pre-
vious model that incorporates DC vaccine injections. We
gather all the equations here for clarity.
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Figure 5: As anti-PD-L1 blocks the PD-1/PD-L1 pathway used by tumor cells to inhibit TCR signaling, an increase
in anti-PD-L1 concentration leads to more TCR activation, quantified using TCR-mediated luminescence. Recreated
from Figure 5 in [21].
Figure 6: Parameters d, r, cpd, and kpd are fit to the tumor growth data for each mouse using MATLAB’s fminsearch
to minimize the sum of squared residuals. In the color-printed version, the colors of the curves alternate for easier
visibility.
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6.1 Final Tumor Compartment
Equations
d
dt
X = −δX (18)
d
dt
Z = −γZ (19)
d
dt
Eatumor = µBB
T
α+ T
Eablood − aEaTEatumor (20)
− cEatumorT
d
dt
T =
r
1 + cibX
T
(
1− T
k
)
−FDT (21)
d
dt
Dtumor =
mT
q + T
− (µTB + aD)Dtumor (22)
+ vtumor(t)
where
F = cpd − 1
pi
(
tan−1 ((Z − 1) · kpd) + pi
2
)
+ 1
D = d
(
Eatumor
T
)l
s+
(
Eatumor
T
)l
Having fit new parameters to the model, we are now in
a position to explore combination therapies.
6.2 Simulations
Using MATLAB’s rand function, we pick random d
and r values uniformly distributed on [0.029, 0.2091] and
[0.2062, 0.3909], respectively, since these are all viable pa-
rameter values from previous fits. The methodology for
choosing these parameter values can be improved with
enough data on the distributions of d and r for the patient
population. Though normal distributions are commonly
used for unknown distributions, we choose to randomize
uniformly distributed values since each pair of r and d is
sufficiently feasible, and the fitted d and r values do not
follow normal distributions. The ranges above were ob-
tained by finding the minimum and maximum values of
d and r from previous fits, omitting outlying d (and their
corresponding r) values (See Figure 7). These initial sim-
ulations consist of 13 runs to compare side-by-side with
experimental outcomes.
As in the experiments conducted in [24], a combination
of both ibrutinib and anti-PDL1 was more effective than
each treatment alone. The importance of these simula-
tions is that they demonstrate how separate experimental
data can be used to predict the outcomes of a combined
effect.
Additionally, new treatment strategies can be devel-
oped by simulating changes to treatment design. First,
we experiment with different anti-PD-L1 dosages. We
run 1000 simulations for each anti-PD-L1 dose from 0.2
to 0.28 mg in increments of 0.001 (See Figure 8). For each
dosage, we note the proportion of simulations for which
the tumor cell population is completely eradicated, and
plot this proportion against the anti-PD-L1 dose. We
note that the proportion remains relatively constant at
approximately 0.5 for doses between 0.2 mg and 0.25 mg,
after which the proportion rises quickly to approximately
0.73, and remains relatively constant as the dose increases
to 0.28 mg. This behavior is consistent with the “switch-
like” effect of the drug on the T cell receptor activation,
and is robust despite the variability in the tumor growth
and kill rate parameters.
Using the information from Figure 8, we look more
closely at tumor growth for the combined treatment group
with an anti-PD-L1 dosage of 0.25 mg. The results for
this set of simulations are shown in Figure 9.
Another possible adjustment to the combined therapy
is to maintain the anti-PD-L1 dose at 0.2 mg, but imple-
ment a different treatment schedule. Instead of injecting
anti-PD-L1 every other day, we experiment with a daily
schedule. Figure 10 shows that a daily schedule yields
better results than the original schedule, with tumor cells
surviving and growing logistically in only 2 out of 13 in-
dividuals. The number of trials can easily be increased to
100 or more trials for a more powerful set of simulations.
We choose to run 13 simulations to compare qualitatively
with existing data for a preliminary analysis.
An additional set of 100 simulations with an adjusted
daily schedule from days 5–10 yielded 85 cases of success-
ful tumor eradication, suggesting the benefits of tweak-
ing scheduling strategies. Using this information, we fur-
ther look at the combined effect of daily scheduling and a
higher dosage of anti-PD-L1 on tumor eradication. Fig-
ure 11 provides a glimpse into these effects.
7 Conclusion
The mathematical model described in this paper can serve
as a powerful tool for cancer treatment design. Optimal
combinations, doses, and scheduling of treatments can be
efficiently predicted to speed up the development of in-
dividualized therapies. In this paper, we have used the
model to study the effect of varying the dosage and treat-
ment scheduling of one of the anti-PD-L1 drug. This
serves an example of future studies in which treatment
regimens of both drugs, as well as the vaccine itself, are
varied. Studying patient-specific parameters such as d
and r may improve our understanding of the treatment
adjustments necessary for successful and nontoxic out-
comes.
An optimal cancer treatment strategy would require
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Figure 7: These simulations recreate behavior from the combined treatment experiments in [24]. Since r and d values
are randomly chosen to simulate immune and tumor diversity, we cannot compare each curve to data individually,
due to the lack of information about each mouse in the data. We are rather interested in qualitative behavior to
confirm the model. Additionally, the difference in proportions between this group of simulations (tumor survived
in 7 out of 13 mice) and the experimental non-treated group (tumor survived in 13 out of 13 mice) is significant at
p < 0.01. When compared to the group treated with anti-PD-L1 (tumor survived in 11 out of 13 mice), the difference
is also significant at p < 0.01.
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Figure 8: 1000 simulations were run for each anti-PD-L1 dosage, from 0.2 mg to 0.28 mg, with increments of 0.001 mg.
For a fixed anti-PD-L1 dose, 1000 values of the parameters r (tumor growth rate) and d (maximum tumor kill rate
by effector cells) were chosen uniformly from the intervals r ∼ U([0.2062, 0.3909]) and d ∼ U([0.029, 0.2091]). These
ranges were determined from the maximum and minimum parameter values estimated from the experimental data
shown in [24]. The graph shows the proportion of successful treatments, where the tumor was eradicated, out of
1000 simulations at the corresponding anti-PD-L1 dosage. We note that this proportion shows a distinct increase
from approximately 0.5 to approximately 0.73 at doses just above 0.25 mg. All other parameters are as given in
Appendix A.
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Figure 9: Changing the anti-PD-L1 dosage from 0.2 mg to 0.25 mg resulted in 71 cases of successful tumor eradication
out of 100 simulations. Successful treatments are indicated by solid blue lines, while unsuccessful treatments are
indicated by dashed black lines.
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Figure 10: Adjusting the anti-PD-L1 dosing schedule from every 2 days from days 5–20 to every day from days 5–10
yields better outcomes (p < 0.05) than from the simulated combined therapy in Figure 7.
Figure 11: 100 simulations were run using the new daily schedule from days 5–10, in addition to an increased anti-
PD-L1 dosage of 0.25 mg. A combination of schedule and dosage adjustment led to 98 cases of successful tumor
eradication out of 100 simulations.
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low toxicity, minimized costs, and a high probability of
cure. Finding the right balance between the pros and
cons of a particular treatment is important for healthy
long term effects, and can benefit from patient-specific
approaches. In this mathematical model, some parame-
ters that need to be measured for each individual are tu-
mor growth rate (r) and “immune ability” determined by
maximal tumor kill rate by T cells (d). As demonstrated
above, these parameters help determine the tumor size
outcome, with zero tumor cells as the ultimate goal.
The model could also benefit from examining other im-
mune checkpoint inhibitors such as CTLA-4, another pro-
tein that helps regulate immune responses [1]. Addition-
ally, the initial model and simulations could be combined
with new human data to study the potential outcomes
of cancer vaccines combined with monoclonal antibodies
like anti-PD-L1.
Though the model was calibrated to mouse data, it
can similarly be adjusted to fit human data and predict
treatment outcomes. With enough data on individual
or combined treatments, the model can be used to re-
imagine personalized therapies.
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Appendix A
Table 4: Tumor Compartment Parameters
Parameter Description Value Units Source
aD Death rate of DCs 0.2310 1/day [16]
aEaT Death rate of activated T cells in tumor 0.462 1/day [16]
α Component of µBTE 1 cells [16]
c Rate for the deactivation of T cells by tumor cells 9.42× 10−12 1/(cell day) [16]
d Maximal fractional tumor kill by activated T cells 1.0497 1/day [16]
k Carrying capacity of the tumor 1× 109 cells [16]
l Scaling exponent for immune strength 2/3 unit-less [16]
m Maximum recruitment rate of DCs to tumor cite 2.4388× 104 cells/day [16]
µBB
Scaled and shifted elimination rate
of activated T cells from blood
5.7 1/day [16]
µTB Transfer rate of DC from tumor to blood 0.0011 1/day [16]
q T-value necessary for half-maximal DC recruitment 100 cells [16]
r Tumor growth rate 0.1655 1/day [16]
s
Value of (Eatumor/T )
l necessary
for half-maximal activated T cell toxicity
1.4 unit-less [16]
Table 5: New Tumor Compartment Parameters
Parameter Description Value Units Source
cib
Scales X, the amount of Ibrutinib,
to a non-dimensionalized value
6.61e-5 mg−1 Fit to [24]
cpd
Scales Z, the amount of Anti-PD-L1
to a non-dimensionalized value
50 mg−1 Fit to [24]
kpd
Scalar for switch function, F ,
to model effects of Anti-PDL1
97 mg−1 Fit to [24]
Table 6: Blood Compartment Parameters
Parameter Description Value Units Source
µB Flow rate of DC from blood 27.072 1/day [16]
µBB Scaled Elimination rate of CTL from blood 5.7 1/day [16]
µnormal Transfer rate of Normal DC from spleen to blood 0.512 1/day [16]
µ∗SB DC Transfer rate from spleen to blood 0.012 1/day [16]
µTB Transfer rate of DC from tumor to blood 0.0011 1/day [16]
θshut Scaled threshold in DC density 1.3 Cells [16]
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Table 7: Spleen Compartment Parameters
Parameter Description Value Units Source
aD Death Rate of DCs 0.2310 1/day [16]
aEaS Death Rate of activated T cells in spleen 0.1199 1/day [16]
aEm Death rate of memory T cells in spleen 0.01 1/day [16]
β
1/time spent in P compartment
= average number of T cells leaving P in unit time
1 1/day [16]
βE number of offspring from activated T cells transitioning to E
a 12 1/day [16]
γ Probability that 1 DC binds in unit time 0.12 1/day [16]
λ Average exit rate of activated T cells from W to P per unit time 4/3 1/day [16]
λM Proliferation of memory T cells in unit time 0.01 1/day [16]
µBS Rate of Transfer for DCs from blood to spleen 2.832 1/day [16]
µBSE
Rate of Transfer (Scaled) for activated T cells
from blood to spleen
7.33× 10−4 1/day [16]
µnormal Transfer rate for normal DC from spleen to blood 0.512 1/day [16]
µ∗SB DC transfer rates from spleen to blood 0.012 1/day [16]
ω Average number of nascent T cells that a DC binds to 5 cells [16]
ram Rate of reversion of activated T cells to memory T cells 0.01 1/day [16]
θshut
Scaled threshold in DC density in spleen
for half-maximal transfer rate from spleen to blood
1.3 cells [16]
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